Sign up to save your podcasts
Or
Share Paul Powell, Jamie Platt | Office Hours: The Human Experience
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Paul Powell, Jamie Platt | Office Hours: The Human Experience
Paul Powell
After taking over his family’s business, Paul Powell experienced a dramatic financial downfall—losing the millions he had earned from the sale of his successful investment practice. While it was a devastating loss at the time, Paul now considers it one of the greatest turning points of his life. That moment of hardship became the catalyst for personal transformation, resilience, and a renewed sense of purpose that continues to guide his journey today.
Jamie Platt
Jamie Platt is the CEO of Pictor Diagnostics and a seasoned leader with over 20 years of experience in genomics and molecular diagnostics. She has played a pivotal role in the development and global commercialization of more than 40 high-complexity laboratory-developed tests (LDTs) and in vitro diagnostics (IVDs). As COO of PGDx and Inivata—both of which were acquired in M&A deals totaling nearly $1 billion—Jamie led successful launches of liquid biopsy products, raised $25 million in capital, and helped guide Inivata from R&D through early commercialization, introducing two products valued at $8.64 billion. At Quest Diagnostics, she was a pioneer in next-generation sequencing (NGS) clinical assays and product lines.
View all episodes
By David MeltzerPaul Powell
After taking over his family’s business, Paul Powell experienced a dramatic financial downfall—losing the millions he had earned from the sale of his successful investment practice. While it was a devastating loss at the time, Paul now considers it one of the greatest turning points of his life. That moment of hardship became the catalyst for personal transformation, resilience, and a renewed sense of purpose that continues to guide his journey today.
Jamie Platt
Jamie Platt is the CEO of Pictor Diagnostics and a seasoned leader with over 20 years of experience in genomics and molecular diagnostics. She has played a pivotal role in the development and global commercialization of more than 40 high-complexity laboratory-developed tests (LDTs) and in vitro diagnostics (IVDs). As COO of PGDx and Inivata—both of which were acquired in M&A deals totaling nearly $1 billion—Jamie led successful launches of liquid biopsy products, raised $25 million in capital, and helped guide Inivata from R&D through early commercialization, introducing two products valued at $8.64 billion. At Quest Diagnostics, she was a pioneer in next-generation sequencing (NGS) clinical assays and product lines.